Cargando…

A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients

In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Engels, Svenja, Michalik, Bianca, Dirks, Lena, van Oosterom, Matthias N., Wawroschek, Friedhelm, Winter, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604386/
https://www.ncbi.nlm.nih.gov/pubmed/37893150
http://dx.doi.org/10.3390/biomedicines11102779
_version_ 1785126823108018176
author Engels, Svenja
Michalik, Bianca
Dirks, Lena
van Oosterom, Matthias N.
Wawroschek, Friedhelm
Winter, Alexander
author_facet Engels, Svenja
Michalik, Bianca
Dirks, Lena
van Oosterom, Matthias N.
Wawroschek, Friedhelm
Winter, Alexander
author_sort Engels, Svenja
collection PubMed
description In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the first in-human case series on exploring the use of a fluorescent–magnetic hybrid tracer in a radiation-free sLND procedure. Superparamagnetic iron oxide nanoparticles and indocyanine green were administered simultaneously in five prostate cancer patients scheduled for extended LND, sLND and radical prostatectomy. In situ and ex vivo fluorescence and magnetic signals were documented for each LN sample detected via a laparoscopic fluorescence imaging and magnetometer system. Fluorescence and magnetic activity could be detected in all patients. Overall, 19 lymph node spots could be detected in situ, 14 of which were fluorescently active and 18 of which were magnetically active. In two patients, no fluorescent LNs could be detected in situ. The separation of the LN samples resulted in a total number of 30 SLNs resected. Ex vivo measurements confirmed fluorescence in all but two magnetically active SLNs. One LN detected in situ with both modalities was subsequently shown to contain a metastasis. This study provides the first promising results of a bimodal, radiation-free sLND, combining the advantages of both the magnetic and fluorescence approaches.
format Online
Article
Text
id pubmed-10604386
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106043862023-10-28 A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients Engels, Svenja Michalik, Bianca Dirks, Lena van Oosterom, Matthias N. Wawroschek, Friedhelm Winter, Alexander Biomedicines Communication In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was introduced to improve sentinel LN (SLN) detection. We present the first in-human case series on exploring the use of a fluorescent–magnetic hybrid tracer in a radiation-free sLND procedure. Superparamagnetic iron oxide nanoparticles and indocyanine green were administered simultaneously in five prostate cancer patients scheduled for extended LND, sLND and radical prostatectomy. In situ and ex vivo fluorescence and magnetic signals were documented for each LN sample detected via a laparoscopic fluorescence imaging and magnetometer system. Fluorescence and magnetic activity could be detected in all patients. Overall, 19 lymph node spots could be detected in situ, 14 of which were fluorescently active and 18 of which were magnetically active. In two patients, no fluorescent LNs could be detected in situ. The separation of the LN samples resulted in a total number of 30 SLNs resected. Ex vivo measurements confirmed fluorescence in all but two magnetically active SLNs. One LN detected in situ with both modalities was subsequently shown to contain a metastasis. This study provides the first promising results of a bimodal, radiation-free sLND, combining the advantages of both the magnetic and fluorescence approaches. MDPI 2023-10-13 /pmc/articles/PMC10604386/ /pubmed/37893150 http://dx.doi.org/10.3390/biomedicines11102779 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Engels, Svenja
Michalik, Bianca
Dirks, Lena
van Oosterom, Matthias N.
Wawroschek, Friedhelm
Winter, Alexander
A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title_full A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title_fullStr A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title_full_unstemmed A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title_short A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
title_sort fluorescent and magnetic hybrid tracer for improved sentinel lymphadenectomy in prostate cancer patients
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604386/
https://www.ncbi.nlm.nih.gov/pubmed/37893150
http://dx.doi.org/10.3390/biomedicines11102779
work_keys_str_mv AT engelssvenja afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT michalikbianca afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT dirkslena afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT vanoosterommatthiasn afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT wawroschekfriedhelm afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT winteralexander afluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT engelssvenja fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT michalikbianca fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT dirkslena fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT vanoosterommatthiasn fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT wawroschekfriedhelm fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients
AT winteralexander fluorescentandmagnetichybridtracerforimprovedsentinellymphadenectomyinprostatecancerpatients